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ABSTRACT 
Objective: The present study was undertaken to investigate the effects of 3-aminobenzamide (3-AB), a poly (ADP-ribose) polymerase 1 (PARP1) 
inhibitor, on motor functions along with brain excito toxicity and bioenergetics alterations in 3-nitropropionic acid (3-NPA) intoxicated mice model 
of Huntington’s disease (HD). 
Methods: Young healthy male C57BL/6J mice were pre-treated with vehicle/3-AB for a period of five days and intoxicated with two doses of 3-NPA 
(15 mg/kg, i. p) at 24 h interval on day 4 and 5. Animals were observed for motor functions 5 days after 3-NPA injection. They were sacrificed at the 
end of motor tests and brains were collected for neurochemical, bioenergetics, glial cells and cytokines analysis. 
Results: 3-AB treatment significantly increased the bioenergetics (ATP and NAD) and succinate dehydrogenase activity in 3-NPA intoxicated mice 
brains. But, it failed to decrease glutamate content, cytokines-TNFα and IL-1β and glial markers–glial fibrillary acidic protein (GFAP) and ionized 
calcium-binding adapter molecule 1 (IBA1) expressions. Further, 3-AB administered produced only a non-significant restoration of motor functions 
in 3-NPA intoxicated mice.  
Conclusion: The present study revealed that excito toxicity and inflammatory pathways are major perpetrators in 3-NPA induced neuro 
degeneration and motor dysfunction. Therapeutic approach with 3-AB alone may not be sufficient to manage the multi-cascade pathogenetic 
mechanisms in HD neither symptomatic management too. 
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INTRODUCTION 
Huntington’s disease (HD) is a neurodegenerative disorder, which 
affects mainly the basal ganglia in the brain. It is clinically 
characterized by a triad of motor dysfunctions, cognitive and 
psychiatric impairments. Though various biochemicals, molecular 
and pathological changes were extensively studied [1-3], the major 
targets in the pathogenesis of HD are not clear. Earlier reports have 
revealed that alterations in mitochondrial functions, in particular, 
succinate oxidation and energy depletion were observed in HD 
patients [4-6]. On the other hand, experimental reports also indicate 
the selective vulnerability of medium spiny neurons in neostriatum 
to glutamate excitotoxicity which reveals that excitotoxic neuronal 
death is also involved in HD [3].  
PARP-1 is a nuclear enzyme and it is a double edged sword involved 
in cellular functions ranging from DNA repair to cell death. PARP-/-
knockout mice showed decreased expression of inducible nitric 
oxide (iNOS) and TNFα triggered induced lipopolysaccaride (LPS) 
endotoxic shock [7]. This reveals that PARP1 propagates the 
necessary signal for cytokines generation. In addition, PARP1 
inhibitors are shown to modulate brain inflammation through 
bioenergetics, iNOS and NFκB activity [8, 9]. Recent studies showed 
that 3-aminobenzamide (3-AB), a PARP inhibitor, exerts 
neuroprotection by directly inhibiting PARP and indirectly by anti-
inflammatory and anti-apoptotic mechanism in cerebral stroke [10, 
11]. Nam et al. [12] showed the involvement of oxidative stress and 
PARP1 activation in 3-NPA induced cytotoxicity in human 
neuroblastoma cells. 
Though many evidences show the altered glutamatergic 
neurotransmission and energy deficiency come about parallely in 
various neurodegenerative diseases, including HD, but no clear 
information on the predominative perpetrator [3, 13, 14]. Further, 
experimental animal models that mimic these clinical features in HD 
are still a debate. Different animal models have been developed to 
study the vulnerability of striatal neurons to excitotoxicity which 
further triggers neuronal death. 3-nitropropionic acid (3-NPA), a 
neurotoxin, irreversibly inhibits succinate dehydrogenase leading to 
cell death [15]. Succinate oxidation by 3-NPA increases calcium 
influx, in turn iNOS stimulation and nitric oxide production, which 
sparks excitotoxicity and inflammation [16] and hence 3-NPA model 
was currently chosen.  
The present study was undertaken to study whether therapeutic 
intervention with 3-AB, PARP1 inhibitor, alone can alleviate 3-NPA 
induced excitotoxicty, bioenergetics deficiency and finally the motor 
functions in mice model and can be considered for the symptomatic 
management of HD.  
MATERIALS AND METHODS 
Chemicals and reagents 
3-NPA and 3-AB were purchased from Sigma Aldrich, USA. Mouse 
anti GFAP was procured from Cell signalling, USA. Mouse anti IBA-1 
and goat anti-mouse IgG were obtained from Santacruz 
Biotechnology, USA. BCIP/NBT substrate was procured from 
GeNei™, Mumbai. All other chemicals used were of analytical grade. 
Animal husbandry and ethics approval 
Male C57BL/6J mice (18-22g b. wt.) were used for the study. Animals 
were housed in groups (5 animals/cage) in polypropylene cages (air 
cycles: 12–15 air changes/h) under an ambient temperature of 22±3 °C 
and 30–70% relative humidity, with a 12-h light/dark artificial photo 
cycle. They were provided with extruded rodent feed (M/s. Provimi Pvt., 
Ltd., India) and purified water, ad libitum. Guidelines of “Guide for the 
Care and Use of Laboratory Animals” were strictly followed. The 
protocol was approved by Institutional Animal Ethics Committee, Sri 
Ramachandra University, Chennai (IAEC/XXII/SRU/161/2011). 
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Groups and treatment 
Animals were acclimatized to the laboratory conditions for a period 
of 7 days. Following acclimatization, animals were grouped into 3 
(10 animals in each) and pre-trained in beam walk test. Treatment 
was scheduled for five consecutive days. Group I and II received 
0.5% carboxy methyl cellulose (CMC) and group III received 3-AB 
(20 mg/kg b. wt., i. p.) once daily. On day 4 and 5, Group II and III 
received 3-NPA (15 mg/kg b. wt., i. p.) half an hour after vehicle/3-
AB administration. Animals were subjected to motor function 
assessment 5 days after 3-NPA injection, sacrificed and brain 
collected for further analysis. 
Motor function 
Beam walk experiment 
Beam walk test was performed according to the Schallert method 
[17] with slight modifications. Mice were pre-trained before 
treatment, to traverse a narrow beam of 100 cm lengths to reach an 
enclosed escape platform. A bright light (20 lux) was placed above 
the narrow beam to create an aversive stimulus. This encourages the 
mice to traverse the beam to the dark enclosed goal box. The mice 
were placed individually at the start of the beam, 24 h after the last 
3-NPA injection. The time taken by the mice to traverse from start of 
the beam to enclosed escape platform, number of foot slips and 
immobility period were recorded. The observer who scored the 
behavior of mice was blinded to the treatment groups.  
Horizontal grid test 
Horizontal grid test was performed according to Kim et al. method 
[18] with slight modifications. Apparatus consisted of horizontal 
grid mesh (total size 12 cm2: openings 0.5 cm2) mounted 20 cm 
above a hard surface, thus discouraging falling but not leading to 
injury in the case of falling. Mice were placed individually in the 
centre of the horizontal grid and supported until it grabs the grid 
with both fore and hind paws. Grid was then inverted so that the 
mouse hangs upside down and they were monitored for hanging 
time and wall fault time. The observer who scored the behavior of 
mice was blinded to the treatment groups. 
Brain glutamate content  
Animals were sacrificed following motor function test, brains were 
isolated, cortical, and striatal regions were micro-dissected and 
processed for glutamate estimation [19]. Brain homogenates were 
prepared in 0.1N HCl in 80% ethanol (for every 10 mg tissue/200 
µl), centrifuged and supernatant was collected. Fresh supernatant 
was used for glutamate estimation using HPTLC (CAMAG–version 
1.3.4, USA). Chromatographic conditions were as follows-stationary 
phase: silica gel GF254; mobile phase: n-butanol: glacial acetic acid: 
water (65:15:25, v/v/v); applicator: Linomat V; scanner: CAMAG 
TLC scanner III; developing chamber: twin trough glass chamber 
(20×10 cm); developing mode: ascending mode (multiple 
development–2 times); detection reagent: 0.2% ninhydrin in 
acetone; scanning wavelength: 486 nm and experimental condition: 
25±2 °C temp/RH: 40–65%. Freshly prepared L-glutamic acid was 
used as standard and calibration curve was plotted with standard at 
20-200 ng concentrations. 
Brain Succinate dehydrogenase (SDH) assay  
Brain SDH activity was performed as previously described [20]. The 
tissue homogenate was diluted with 2.0 ml of cell extraction buffer. 
Assay mixture consists of 1.0 ml of 0.4 M potassium phosphate 
buffer (pH 7.2), 40 μl of 0.15 M sodium succinate (pH 7.0); 40 μl of 
0.2 M sodium azide and 10 μl of 6.0 mg/ml 2,6-Dichlorophenol 
Indophenol (DCPIP). This mixture was used to obtain the baseline 
(zero) of the spectrophotometer reading at 600 nm. To 1.1 ml of this 
mixture, 200 μl of the sample was added. The rate of change in 
absorbance per minute was used to quantify the enzyme activity 
using the extinction co-efficient (19.1 MN-1 cm-1) of DCPIP. 
Bioenergetics (NAD+and ATP content) 
Cortical and striatal regions were processed for bioenergetics 
estimation. The specified brain regions were homogenized with 10% 
KCl used for the estimation of NAD+ and ATP level as described 
previously [21] with slight modifications. Homogenate aliquots were 
sonicated in ice-cold perchloric acid (0.1 N). After centrifugation 
(14,000 g, 4 °C, 5 min), 1 N sodium hydroxide were added to 
neutralise the supernatant. ATP/NAD+levels were determined using 
a reversed-phase high performance liquid chromatography (RP-
HPLC) (Perkin Elmer, India). 
ELISA 
Inflammatory markers such as TNF-α and IL-1β levels were 
measured following ELISA kit method (Ebioscience, Inc. USA). 
Immunoblotting 
Striatal and cortical tissue samples were homogenised in 0.1 M ice 
cold Tris hydrochloric acid (pH 7.4) and centrifuged at 3500 rpm for 
10 min. Protein concentrations of the supernatant were measured 
using Bradford reagent [22]. Aliquots containing 10 μg total proteins 
per sample were mixed with sample loading dye (β-
mercaptoethanol and bromophenol blue) and electro phoresed on 
12% sodium deodecyl sulphate polyacrylamide gel (Hoefer, USA). 
Separated proteins were transferred to polyvinylidene difluoride 
membranes, which were blocked overnight in 3% bovine serum 
albumin in Tris-buffered saline. Membranes were then washed 
thrice for 5 min each in Tris buffered saline and probed with 
primary antibodies. After three 5 min washes in TBS, membranes 
were probed with secondary antibodies for 1 h then washed again in 
TBS and incubated in BCIP/NBT substrate for alkaline phosphatise 
kit for 10 min. Bands obtained were visualised and semi-quantified 
using Bio1D software in gel documentation (Vilber Loumart, 
France). The following primary antibodies were used: mouse anti 
GFAP (1:500) and mouse anti IBA-1 (1:200). Goat anti-mouse IgG 
(1:1000) was used as the secondary antibody. 
Statistical analysis 
Data was expressed as mean±standard error means (SEM). Mean 
difference between groups were analysed by one way ANOVA 
followed by Tukey’s multiple comparison as post hoc test using 
Graph Pad Prism 5.0 (San Diego, USA) software. p value ≤ 0.05 was 
considered significant. 
RESULTS 
Effect of 3-AB on motor functions in 3-NPA intoxicated mice 
Beam Walk Experiment 
3-NPA mice took longer time (p<0.01) to cross the marked zone and 
increased immobility period (p<0.01) and number of foot slips 
(p<0.01) when compared to the vehicle treated normal mice. 3-AB 
administration showed a non-significant decrease in time taken to 
cross the marked zone, immobility period and number of foot slips 
when compared to 3-NPA intoxicated mice (fig. 1). 
Horizontal grid test 
3-NPA mice showed the significant decrease (p<0.01) in hang time 
when compared to the vehicle treated normal mice. 3-AB 
administration showed no significant difference in hang time in 
comparison to 3-NPA intoxicated mice (fig. 2). 
Effect of 3-AB on brain glutamate content in 3-NPA intoxicated 
mice  
A significant increase in glutamate content was observed in striatal 
(p<0.01) and cortical (p<0.05) brain regions of 3-NPA intoxicated 
mice when compared to vehicle treated normal mice. 3-AB 
administration showed no significant difference in glutamate 
content when compared to 3-NPA mice brain (fig. 3). 
Effect of 3-AB on brain succinate dehydrogenase activity in 3-
NPA intoxicated mice 
A significant decrease (p<0.01) in succinate dehydrogenase activity 
was observed in striatal and cortical brain regions of 3-NPA 
intoxicated mice when compared to vehicle treated normal mice. 
Pre-treatment with 3-AB significantly (p<0.01) increased the activity 
in comparison to 3-NPA mice brain (fig. 4). 
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Effect of 3-AB on bioenergetics in 3-NPA intoxicated mice 
A significant decrease (p<0.01) in striatal ATP and NAD+ contents 
was observed in 3-NPA mice brain when compared to vehicle 
treated normal mice. 3-AB administration significantly (p<0.01) 
increased the striatal ATP and NAD+ contents in comparison to 3-
NPA mice brain (fig. 5). There was no difference in cortical ATP and 
NAD+ contents between the groups. 
 
Effect of 3-AB on inflammatory markers in 3-NPA intoxicated mice 
A significant increase in TNFα (p<0.01) and IL-1β (p<0.05) levels 
were observed in striatal and cortical brain regions of 3-NPA mice 
when compared to vehicle treated normal mice. There was no 
significant decrease in striatal and cortical TNFα and IL-1β levels 
in 3-AB administration were observed when compared to 3-NPA 















































































































Fig. 1: Effect of 3-AB on beam walk experiment. Values were expressed in mean±SEM; n=10 animals/group; statistical analysis was 

































Fig. 2: Effect of 3-AB on horizontal grid test. Values were 
expressed in mean±SEM; n=10 animals/group; statistical 
analysis was performed using one way ANOVA followed by 
Tukey’s multiple comparison test, ## indicates p value<0.01 Vs 



















































Fig. 3: Effect of 3-AB on glutamate content in 3-NPA intoxicated 
mice brain. Values were expressed in mean±SEM; n=3 
animals/group; statistical analysis was performed using one way 
ANOVA followed by Tukey’s multiple comparison test, #,## indicates 
p value<0.05 and 0.01, respectively Vs vehicle treated group 
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Fig. 4: Effect of 3-AB on succinate dehydrogenase activity in 3-
NPA intoxicated mice brain. Values were expressed in 
mean±SEM; n=3 animals/group; statistical analysis was 
performed using one way ANOVA followed by Tukey’s multiple 
comparison test, ## indicates p value<0.01 Vs vehicle treated 
group; ** indicates p value<0.01 Vs 3-NPA+Vehicle treated 
group 
 
Effect of 3-AB on glial markers in 3-NPA intoxicated mice 
A significant increase (p<0.01) in GFAP and IBA-1 expressions were 
observed in striatal and cortical brain regions of 3-NPA mice when 
compared to vehicle treated normal mice. Pre-treatment with 3-AB 
showed no significant difference in GFAP and IBA-1 expressions 
when compared to 3-NPA mice (fig. 7). 
DISCUSSION 
Impaired mitochondrial functions through complex II inhibition, 
altered bioenergetics and increased excitotoxicity exacerbates the 
progression of neurodegeneration in HD [23]. In the present study, 
3-AB increased succinate dehydrogenase activity and bioenergetics 
ATP and NAD+contents in 3-NPA intoxicated mice brain. However, 3-
AB failed to restore glutamate excitotoxicty and inflammatory 
events.  
It is well known that mitochondria play a key role in cell survival by 
regulating energy metabolism, apoptosis and calcium homeostasis 
[24, 25]. Reduction of mitochondrial complex II/III activity was 
observed in caudate and putamen brain regions of HD patients [26]. 
Furthermore, cultured striatal neurons injected with huntingtin 
(Htt) protein revealed a marked decline in complex II/succinate 
dehydrogenase activity which precedes energy depletion and 
neuronal cell death [27]. Estrada Sánchez et al. [3] showed that 
exposure to 3-NPA generated metabolic inhibition and 
mitochondrial dysfunctions that were shown to be due to oxidative 
stress, DNA strand break and PARP activation in human 
neuroblastoma cells. The increased succinate dehydrogenase 
activity and bioenergetics contents (ATP and NAD+) in the present 
study revealed that 3-AB to suppress the cellular consumption of 
ATP and NAD+through direct inhibition of over-activated PARP1. 
Various studies demonstrated that NMDA antagonist, MK-801 and 
memantine exert protection against striatal lesions by suppressing 
excitotoxicity and improving succinate dehydrogenase activity in 3-
NPA mice model [28, 29]. It has been shown that the glutaminergic 
system contributes to the neuronal cell death by NMDA receptor 
activation with excitotoxicity in HD [30, 31]. PPAR inhibition by 3-
AB, decreased injury after focal ischemia in rats through reducing 
NMDA induced glutamate efflux and neurotransmitter dysfunction 
[32]. In the present study, pre-treatment with 3-AB did not showed 
any effect on glutamate level, i. e excitotoxicity. This is reveals 
meager restoration of bioenergetics may not alleviate excitotoxicity 





































































































Fig. 5: Effect of 3-AB on bioenergetics (ATP and NAD+levels) in 3-NPA intoxicated mice brain. Values were expressed in mean±SEM; n=3 
animals/group; statistical analysis was performed using one way ANOVA followed by Tukey’s multiple comparison test, ## indicates p 
value<0.01 Vs vehicle treated group; ** indicates p value<0.01 Vs 3-NPA+Vehicle treated group 
 
Another vital component that contributes to the vulnerability of 
striatal neurons to excitotoxicity is the surrounding glial cells 
[33]. Activation of glial cells in turn stimulates the inflammatory 
processes. Intoxication with 3-NPA was shown to up-regulate 
GFAP and IBA1 expressions in experimental animal model [34]. 
Recently, we have shown a strong positive correlation between 
the glutamate content and GFAP expression in 3-NPA mice model 
of HD. In the present study, 3-AB failed to down-regulate GFAP 
and IBA1 and also the cytokines TNFα and IL-1β levels in 3-NPA 
intoxicated mice which could be speculated to failure to control 
excitotoxicity. Further, alleviation of excitotoxicity was seemed 
to be more essential than bioenergetics restoring motor function 
in HD. Also, striatal region was found to be more vulnerable to 3-
NPA toxicity than cortical region. These data reveal that 
alleviation bioenergetics will not be sufficient in the treatment of 
HD. 
Babu et al. 












































































Fig. 6: Effect of 3-AB on inflammatory markers (TNFα and IL-1β) in 3-NPA intoxicated mice brain. Values were expressed in mean±SEM; 
n=3 animals/group; statistical analysis was performed using one way ANOVA followed by Tukey’s multiple comparison test, #,## indicates 





















































































Fig. 7: Effect of 3-AB on glial markers (GFAP and IBA-1) in 3-NPA intoxicated mice brain. Values were expressed in mean±SEM; n=4 
animals/group; statistical analysis was performed using one way ANOVA followed by Tukey’s multiple comparison test, ## indicates p 
value<0.01 Vs vehicle treated group. Representative bands were shown below the graph. Lane 1 and 2 represents striatal and cortical 
vehicle treated mice brain; Lane 3 and 4 represents striatal and cortical 3-NPA intoxicated mice brain; Lane 5 and 6 represents striatal 
and cortical 3-AB administered mice brain 
 
CONCLUSION 
In conclusion, 3-AB plays a main role in restoring the succinate 
dehydrogenates activity and bioenergetics in 3-NPA mice brain. 
However, inhibition of glutamate excitotoxicity in turn gliosis and 
inflammation seem to be more essential in controlling the disease 
progression and secondary molecular events as well in HD than 
bioenergetics restoration.  
ACKNOWLEDGEMENT 
Authors express their sincere thanks to Prof. S. Thanikachalam, 
Director–Centre for Toxicology and Developmental Research 
(CEFT), Sri Ramachandra University, for providing the facility to 
carry out the study. Authors also thank all technical and non-
technical staff of CEFT for their help during study conduction. 
ABBREVIATION 
PARP1-Poly (ADP-ribose) polymerase 1; 3-AB-3-aminobenzamide; ATP-
Adenosine triphosphate; NAD-Nicotinamide adenine dinucleotide; 3-
NPA-3-nitropropionic acid; HD-Huntington’s disease; TNFα-Tumor 
necrotic factor α; IL-1β-Interleukin 1β; GFAP-Glial fibrillary acidic 
protein; IBA1-Ionized calcium-binding adapter molecule 1; CMC–
Carboxy methyl cellulose; DCPIP-2,6-Dichlorophenol Indophenol. 
CONFLICT OF INTERESTS 
Author declares no conflict of interest 
Babu et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 8, 121-126 
126 
REFERNCES 
1. Cha JH. Transcriptional dysregulation in huntington’s disease. 
Trends Neurosci 2000;23:387–92. 
2. Rangone H, Humbert S, Saudou F. Huntington’s disease: How 
does huntingtin, an antiapoptotic protein, become toxic? Pathol 
Biol 2004;52:338–42. 
3. Estrada-Sanchez AM, Mejia-Toiber J, Massieu L. Excitotoxic 
neuronal death and the pathogenesis of Huntington’s disease. 
Arch Med Res 2008;39:265–76. 
4. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: 
A mitochondrial toxin to uncover physiopathological 
mechanisms underlying striatal degeneration in Huntington's 
disease. J Neurochem 2005;95:1521–40. 
5. Kumar P, Kumar A. Protective effect of rivastigmine against 3-
nitropropionic acid-induced Huntington’s disease like 
symptoms: Possible behavioural, biochemical and cellular 
alterations. Eur J Pharmacol 2009;615:91–101. 
6. Túnez I, Santamaria A. Model of Huntington’s disease induced 
with 3-nitropropionic acid. Rev Neurol 2009;48:430–4. 
7. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, 
Andriantsitohaina R, Muller S, et al. Resistance to endotoxic 
shock as a consequence of defective NF-kappaB activation in 
poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 
1999;18:4446–54. 
8. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 
activity promotes NF-kappaB-driven transcription and 
microglial activation: implication for neurodegenerative 
disorders. J Neurochem 2003;85:306–17. 
9. Ullrich O, Diestel A, Eyupoglu IY, Nitsch R. Regulation of 
microglial expression of integrins by poly(ADP-ribose) 
polymerase-1. Nat Cell Biol 2001;3:1035–42. 
10. Koh S, Chang D, Kim H, Kim J, Kim M, Kim KS, et al. Effect of 3-
aminobenzamide, PARP inhibitor, on matrix metalloproteinase-
9 level in plasma and brain of ischemic stroke model. 
Toxicology 2005;214:131–9. 
11. Strosznajder R, Gajkowskar B. Effect of 3-aminobenzamide on 
Bcl-2, Bax and AIF localization in hippocampal neurons altered 
by ischemia-reperfusion injury. The histochemical study. Acta 
Neurobiol Exp 2006;66:15-22. 
12. Nam E, Lee YJ, Oh YA, Jung JA, Im HI, Koh SE, et al. Involvement of 
oxidative stress and Poly(ADP-ribose) polymerase activation in 3-
nitropropionic acid-induced cytotoxicity in human neuroblastoma 
cells. Korean J Physiol Pharmacol 2003;7:325-31. 
13. Babu CS, Ramanathan M. Pre-ischemic treatment with 
memantine reversed the neurochemical and behavioural 
parameters but not energy metabolites in middle cerebral artery 
occluded rats. Pharmacol Biochem Behav 2009;92:424–32. 
14. Kalaivani P, Ganesh M, Gayathiri V, Jyothi Priya R, Pramila B, 
Sunil AG, et al. Alterations in SIRT1 and PARP1 expression 
precedes oxidative stress event in rats subjected to transient 
focal cerebral ischemia: Molecular and Histopathological 
evidences. J Stroke Cerebrovascular Dis 2014;23:2753-66. 
15. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M. 3-
Nitropropinic acid-exogenous animal neurotoxin and possible 
human striatal toxin. Can J Neurol Sci 1991;18:492–8. 
16. Tunez I, Tasset I, La Cruz VP, Santamaria A. 3-Nitropropionic 
acid as a tool to study the mechanisms involved in huntington’s 
disease: past, Present and future. Molecules 2010;15:878-16. 
17. Schallert T. Behavioural tests for preclinical intervention 
assessment. Neurotherapeutics 2006;3:497-504. 
18. Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O. Vertical grid test and 
modified horizontal grid test are sensitive methods for 
evaluating motor dysfunctions in the MPTP mouse model of 
Parkinson’s disease. Brain Res 2010;1306:176-83. 
19. Babu CS, Sunil AG, Hannah RV, Muthusamy VS, Ramanathan M. 
Development and validation of an HPTLC method for 
simultaneousestimation of excitatory neurotransmitters in rat 
brain. J Liq Chromatogr Relat Technol 2007;30:2891–902. 
20. Bregman AA. Laboratory Investigations In Cell Biology, viii, 
Wiley, New York: Chichester; 1987. p. 268. 
21. Zhan C, Yang J. Protective effects of isoliquiritigenin in 
transient middle cerebral artery occlusion-induced focal 
cerebral ischemia in rats. Pharmacol Res 2006;53:303-9. 
22. Bradford MM. A rapid and sensitive method for the quantitation 
ofmicrogram quantities of protein utilizing the principle of 
protein-dye binding. Anal Biochem 1976;72:248–54. 
23. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and 
potential therapeutical targets in Huntington’s disease. Physiol 
Rev 2010;90:905–81. 
24. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing 
power for life and unleashing the machineries of death. Cell 
2003;112:481–90. 
25. Green DR, Kroemer G. The pathophysiology of mitochondrial 
cell death. Sci 2004;305:626–9.  
26. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, 
Muqit MM, et al. Oxidative damage and metabolic dysfunction 
in Huntington's disease: selective vulnerability of the basal 
ganglia. Ann Neurol 1997;41:646–53. 
27. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, 
et al. Involvement of mitochondrial complex II defects in 
neuronal death produced by N-terminus fragment of mutated 
huntingtin. Mol Biol Cell 2006;17:1652–63. 
28. Wullner U, Young AB, Penney JB, Beal MF. 3-Nitropropionic 
acid toxicity in the striatum. J Neurochem 1994;63:1772-81. 
29. Ranju V, Sathiya S, Kalaivani P, Priya RJ, Babu CS. Memantine 
exerts functional recovery by improving BDNF and GDNF 
expression in 3-nitropropionic acid intoxicated mice. Neurosci 
Let 2015;586:1–7. 
30. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, 
Brundin P, et al. Increased sensitivity to N-methyl-D-aspartate 
receptor rmediated excitotoxicity in a mouse model of 
Huntington's disease. Neuron 2002;33:849-60. 
31. Schiefer J, Sprunken A, Puls C, Luesse HG, Milkereit A, Milkereit 
E, et al. The metabotropic glutamate receptor 5 antagonist 
MPEP and the mGluR2 agonist LY379268 modify disease 
progression in a transgenic mouse model of Huntington's 
disease. Brain Res 2004;1019:246-54. 
32. Lo EH, Bosque-Hamilton P, Meng W. Inhibition of Poly(ADP-
Ribose) polymerase: reduction of ischemic injury and 
attenuation of N-Methyl-d-Aspartate–Induced 
neurotransmitter dysregulation. Stroke 1998;29:830-6. 
33. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of 
mutant huntingtin in glial cells contributes to neuronal 
excitotoxicity. J Cell Biol 2005;171:1001–12. 
34. Jang M, Lee MJ, Kim CS, Cho I. Korean red ginseng extract 
attenuates 3-nitropropionic acid-induced huntington’s-like 
symptoms. Evidence-Based Complementary Altern Med 
2013;2013:1-17. 
 
